Literature DB >> 15857316

Opioid-modulating peptides: mechanisms of action.

Catherine Mollereau1, Michel Roumy, Jean-Marie Zajac.   

Abstract

Opioids are involved in the physiological control of numerous functions of the central nervous system, particularly nociception. It appears that some endogenous neuropeptides, called anti-opioids, participate in an homeostatic system tending to reduce the effects of opioids. Neuropeptide FF (NPFF) and cholecystokinin (CCK) possess these properties and, paradoxically, the opioid peptides nociceptin and dynorphin display some anti-opioid activity. All these peptides exhibit complex properties as they are able to both counteract and potentiate opioid activity, acting rather as modulators of opioid functions. The purpose of this review is to highlight that two different mechanisms are clearly involved in the control of opioid functions by opioid-modulating peptides: a circuitry-induced mechanism for nociceptin and dynorphin, and a cellular anti-opioid mechanism for NPFF and CCK. The knowledge of these mechanisms has potential therapeutic interest in the control of opioid functions, notably for alleviating pain and/or for the treatment of opioid abuse.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15857316     DOI: 10.2174/1568026053544515

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  19 in total

1.  Effect of the Combination of CI-988 and Morphine on Neuropathic Pain after Spinal Cord Injury in Rats.

Authors:  Junesun Kim; Youngkyung Kim; Suk-Chan Hahm; Young Wook Yoon
Journal:  Korean J Physiol Pharmacol       Date:  2015-02-25       Impact factor: 2.016

2.  Discovery of Novel Proline-Based Neuropeptide FF Receptor Antagonists.

Authors:  Thuy Nguyen; Ann M Decker; Tiffany L Langston; Kelly M Mathews; Justin N Siemian; Jun-Xu Li; Danni L Harris; Scott P Runyon; Yanan Zhang
Journal:  ACS Chem Neurosci       Date:  2017-08-09       Impact factor: 4.418

3.  Nonpeptide small molecule agonist and antagonist original leads for neuropeptide FF1 and FF2 receptors.

Authors:  V Blair Journigan; Christophe Mésangeau; Neha Vyas; Shainnel O Eans; Stephen J Cutler; Jay P McLaughlin; Catherine Mollereau; Christopher R McCurdy
Journal:  J Med Chem       Date:  2014-10-21       Impact factor: 7.446

4.  GRK2 protein-mediated transphosphorylation contributes to loss of function of μ-opioid receptors induced by neuropeptide FF (NPFF2) receptors.

Authors:  Lionel Moulédous; Carine Froment; Stéphanie Dauvillier; Odile Burlet-Schiltz; Jean-Marie Zajac; Catherine Mollereau
Journal:  J Biol Chem       Date:  2012-02-28       Impact factor: 5.157

5.  Heterologous regulation of Mu-opioid (MOP) receptor mobility in the membrane of SH-SY5Y cells.

Authors:  Kévin Carayon; Lionel Moulédous; Anne Combedazou; Serge Mazères; Evert Haanappel; Laurence Salomé; Catherine Mollereau
Journal:  J Biol Chem       Date:  2014-09-02       Impact factor: 5.157

6.  Biological properties and perspective applications of "Bio-neuter" chemicals?

Authors:  Abdelaziz Ghanemi
Journal:  Saudi Pharm J       Date:  2014-01       Impact factor: 4.330

7.  BN-9, a chimeric peptide with mixed opioid and neuropeptide FF receptor agonistic properties, produces nontolerance-forming antinociception in mice.

Authors:  Ning Li; Zheng-Lan Han; Zi-Long Wang; Yan-Hong Xing; Yu-Long Sun; Xu-Hui Li; Jing-Jing Song; Ting Zhang; Run Zhang; Meng-Na Zhang; Biao Xu; Quan Fang; Rui Wang
Journal:  Br J Pharmacol       Date:  2016-04-21       Impact factor: 8.739

8.  Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments.

Authors:  K Elhabazi; J M Trigo; C Mollereau; L Moulédous; J-M Zajac; F Bihel; M Schmitt; J J Bourguignon; H Meziane; B Petit-demoulière; F Bockel; R Maldonado; F Simonin
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

Review 9.  Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential.

Authors:  Marc J Berna; Jose A Tapia; Veronica Sancho; Robert T Jensen
Journal:  Curr Opin Pharmacol       Date:  2007-11-09       Impact factor: 5.547

10.  The roles of nerve growth factor and cholecystokinin in the enhancement of morphine analgesia in a rodent model of central nervous system inflammation.

Authors:  Dimitris N Xanthos; Naresh Kumar; Elvar Theodorsson; Terence J Coderre
Journal:  Neuropharmacology       Date:  2008-12-11       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.